For many decades, cancer research in Europe has been heavily fragmented, inefficient and duplicating work. Now, long-term collaborations have been generated between cancer centres which will carry a new phase of cooperation into the future.
Five years ago, 28 of Europe´s leading cancer institutions and organisations, including the Vall d´Hebron Institute of Oncology (VHIO), joined together as a unique EU-financed partnership — the ‘EurocanPlatform’ to share infrastructures and collaborate on projects aimed at improved outcomes for cancer patients and reduced mortality across Europe through prevention, early detection and improved, more precise therapies.
Predicted to increase significantly globally as the population ages, cancer places a substantial burden on healthcare systems particularly regarding surveillance and recurrent treatment. “We’re faced with this growing cancer burden and at the same time we’re confronted with the spiralling costs of cancer treatment and care”, says Christopher Wild, Director of the International Agency for Research on Cancer (IARC). There is now an urgent need to meet these challenges by developing long-term strategies to accelerate the translation of basic discoveries into clinical and preventive applications.
At the EurocanPlatform´s final Annual Meeting celebrated in Brussels, 03 November 2015,European Commissioner for Research, Innovation and Science, Carlos Moedas, stated that patients should be at the centre of research. Moving to personalised medicine will lead to challenges requiring a link to digital technology and new legal and ethical standards to support international collaborations and compilation of data will be required. There is a need for cancer care that is innovative and cost-effective, and the cancer community needs to provide advice and support.
Now in its final months, EurocanPlatform has produced some important outcomes that are hoped to impact cancer patient outcomes and reduced mortality. “At the Vall d´Hebron Institute of Oncology (VHIO) we are committed to combining strengths to overcome current obstacles that are hampering the acceleration of discovery and thus improved cancer treatment and care across Europe. Strategic cross-border alliances such as the EurocanPlatform and Cancer Core Europe will help to spur advancements and render personalized medicine more precise and accessible for an increasing number of our patients”, observes Josep Tabernero, Director of the Vall d´Hiebron Institute of Oncology (VHIO).
Founded in 2014, Cancer Core Europe (CCE) is led by six founding partners from the EurocanPlatform: the Gustave Roussy Cancer Campus Grand Paris (Villejuif, France), Cambridge Cancer Center (Cambridge, UK), Karolinska Institute (Stockholm, Sweden), Netherlands Cancer Institute (Amsterdam, The Netherlands), National Center for Tumor Diseases – DKFZ-NCT (Heidelberg, Germany) and the Vall d’Hebron Institute of Oncology – VHIO (Barcelona, Spain). This unique undertaking represents a transformative initiative whereby leading comprehensive cancer centers work collectively to address the cancer care – cancer research continuum.
“Since the optimal treatment of cancer remains one of the major medical challenges globally due to the high diversity in the spectrum of mutations in individual cancer patients, among many other implicated factors, Cancer Core Europe is driving towards better integrated cancer programs performed at large scale”, says Josep Tabernero.
Cancer Core Europe will collectively provide powerful translational platforms, inter-compatible clinical molecular profiling laboratories with a robust underlying computational biology pipeline, standardised imaging as well as early clinical trial structures aimed at progressing precision medicine against cancer. Each centre has invested funds towards this important goal.
Spearheaded by Professor Alexander Eggermont and Professor Otmar Wiestler, CCE was first conceived back in 2002, when Commissioner Philippe Busquin promoted the creation of the European Cancer Research Area, indicating that “Europe was not delivering the outcomes expected by healthcare professionals and citizens, and there was a need to create a joint European strategy for cancer research.” EurocanPlatform’s Scientific Coordinator Julio Celis of the Danish Cancer Society Research Centre said: “I believe CCE represents the first organised step in this direction. Hopefully, CCE will be a precursor to a virtual European Cancer Institute”, comments EurocanPlatform´s Scientific Coordinator, Julio Celis of the Danish Cancer Society Research Centre (Copenhagen, Denmark).
Commissioner Carlos Moedas said “As I see it, digital technologies and personalised medicine will provide many of the answers we need to fight cancer in the 21st century. There is a lot we can explore, with the ultimate goal of bringing the digital and the physical together to fight cancer, so that fewer citizens become patients and more patients become survivors”.
Following on from the initial success of CCE, Dr Christopher Wild of IARC plans to create a counterpart initiative: Cancer Prevention Europe. He said, “To really address that challenge we needed not only to focus on improving treatment which is essential, but also trying to address the prevention of the disease and its early detection, and having a more integrated approach across those different areas.”
“I was impressed at the progress that had been made between these major cancer institutes together to form what is now called the Cancer Core Europe. I wanted to introduce a kind of ‘twin-track’ approach, if you like, saying let’s try a similar type of approach regarding cancer prevention.”
Coordinating approaches across centres in cancer prevention is the perfect complement to CCE, giving a symmetrical, sustainable approach to tackling cancer in Europe.
Ulrik Ringborg of the Karolinska Institutet, the project’s coordinating partner, remarked: “The EurocanPlatform has created a multidisciplinary environment to structure research collaboration between preclinical and clinical cancer research centres for translational research aimed at personalized cancer medicine. We are delighted that the EurocanPlatform has been able to deliver important sustainable outcomes which will strengthen Europe’s ability to innovate in cancer research.”
About the EurocanPlatform: The EurocanPlatform is an EU-funded Network of Excellence linking 23 cancer research centres and five cancer organisations aiming at institutional collaborations in translational cancer research to innovate in prevention, early detection and therapeutics. The centres are sharing infrastructures and collaborating on projects to help advance cancer research and treatment.
For more information contact:
Amanda Wren • Director of Communications, the Vall d’Hebron Instituto de Oncología (VHIO) • Tel. +34 695 207 886 email@example.com